Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance |
Autore | Organization World Health |
Pubbl/distr/stampa | Geneva, : World Health Organization, 2014 |
Descrizione fisica | 1 online resource (254 p.) |
Disciplina | 616 |
Soggetto topico |
Drug resistance -- Periodicals
Drug resistance in microorganisms Drug resistance Anti-infective agents - Classification Drug resistance in microorganisms - Effect of drugs on Risk management Risk Risk Management Information Science Drug Resistance Microbiological Phenomena Epidemiologic Measurements Therapeutic Uses Probability Pharmacologic Actions Pharmacological Phenomena Public Health Organization and Administration Statistics as Topic Health Services Administration Environment and Public Health Chemical Actions and Uses Physiological Phenomena Health Care Evaluation Mechanisms Health Care Epidemiologic Methods Drug Therapy Quality of Health Care Investigative Techniques Diagnostic Techniques and Procedures Health Care Quality, Access, and Evaluation Anti-Infective Agents Classification Risk Assessment Drug Resistance, Microbial Biology Health & Biological Sciences Microbiology & Immunology |
Soggetto genere / forma |
Publication Formats
Technical Report |
ISBN | 92-4-069266-5 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material |
Record Nr. | UNINA-9910825162403321 |
Organization World Health
![]() |
||
Geneva, : World Health Organization, 2014 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
Autore | Kazmierski Wieslaw M |
Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
Descrizione fisica | 1 online resource (470 p.) |
Disciplina | 615/.7924 |
Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
Record Nr. | UNINA-9910139613803321 |
Kazmierski Wieslaw M
![]() |
||
Hoboken, : Wiley, 2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
Autore | Kazmierski Wieslaw M |
Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
Descrizione fisica | 1 online resource (470 p.) |
Disciplina | 615/.7924 |
Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
Record Nr. | UNINA-9910808713803321 |
Kazmierski Wieslaw M
![]() |
||
Hoboken, : Wiley, 2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]] |
Autore | Boverhof Darrell R |
Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
Descrizione fisica | 1 online resource (402 p.) |
Disciplina |
616.042
616/.042 |
Altri autori (Persone) | GollapudiB. Bhaskar |
Soggetto topico |
Genetic toxicology
Health risk assessment Risk Assessment Toxicity testing Toxicogenetics Toxicology Pharmacogenetics Risk Risk Management Epidemiologic Measurements Organization and Administration Pharmacology Probability Genetics Public Health Health Occupations Statistics as Topic Biological Science Disciplines Biology Health Services Administration Environment and Public Health Natural Science Disciplines Health Care Health Care Evaluation Mechanisms Epidemiologic Methods Quality of Health Care Investigative Techniques Health Care Quality, Access, and Evaluation Health & Biological Sciences Toxicology & Public Health |
Soggetto genere / forma | Electronic books. |
ISBN |
1-283-23966-3
9786613239662 1-118-00104-4 1-118-00103-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Contents; Preface; Contributors; 1 Toxicology, ""Omics"" Technologies, and Toxicogenomics: A Primer; 2 Introduction to Human Health Risk Assessment; 3 Practical Considerations for the Application of Toxicogenomics to Risk Assessment: Early Experience, Current Drivers, and a Path Forward; 4 Approaches and Practical Considerations for the Analysis of Toxicogenomics Data; 5 Genomics in Identifying Mutagenic Mode of Action in Carcinogenesis; 6 Application of Genomics for Predicting and Understanding the Mode of Action for Nongenotoxic Carcinogens; 7 Genomics in Characterizing Endocrine Toxicity
8 Studying Organ-Specific Toxicity Using Gene-Expression Profiling9 Toxicogenomic Studies in Human Populations; 10 Toxicogenomics Applied to Ecological Risk Assessment; 11 Analysis of Transcriptomic Dose-Response Data for Toxicology and Risk Assessment; 12 Toxicogenomics as a Tool for Validating Animal to Human Extrapolations in Chemical Risk Assessment: Concepts, Applications, and Challenges; 13 Toxicogenomics and Animal Alternatives; 14 Toxicogenomics and the Regulatory Framework; 15 Standardization of Gene-Expression Information for the Safety Evaluation: Activities in Japan 16 Applying Transcriptional Profiling in Drug Safety Evaluation17 Reframing the Risk Assessment Paradigm: Toward a Systems Biology Approach; Index |
Record Nr. | UNINA-9910139607903321 |
Boverhof Darrell R
![]() |
||
Hoboken, : Wiley, 2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]] |
Autore | Boverhof Darrell R |
Edizione | [First edition.] |
Pubbl/distr/stampa | Hoboken : , : Wiley, , 2011 |
Descrizione fisica | 1 online resource (402 pages) |
Disciplina |
616.042
616/.042 |
Altri autori (Persone) | GollapudiB. Bhaskar |
Soggetto topico |
Genetic toxicology
Health risk assessment Risk Assessment Toxicity testing Toxicogenetics Toxicology Pharmacogenetics Risk Risk Management Epidemiologic Measurements Organization and Administration Pharmacology Probability Genetics Public Health Health Occupations Statistics as Topic Biological Science Disciplines Biology Health Services Administration Environment and Public Health Natural Science Disciplines Health Care Health Care Evaluation Mechanisms Epidemiologic Methods Quality of Health Care Investigative Techniques Health Care Quality, Access, and Evaluation Health & Biological Sciences Toxicology & Public Health |
ISBN |
1-283-23966-3
9786613239662 1-118-00104-4 1-118-00103-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Contents; Preface; Contributors; 1 Toxicology, ""Omics"" Technologies, and Toxicogenomics: A Primer; 2 Introduction to Human Health Risk Assessment; 3 Practical Considerations for the Application of Toxicogenomics to Risk Assessment: Early Experience, Current Drivers, and a Path Forward; 4 Approaches and Practical Considerations for the Analysis of Toxicogenomics Data; 5 Genomics in Identifying Mutagenic Mode of Action in Carcinogenesis; 6 Application of Genomics for Predicting and Understanding the Mode of Action for Nongenotoxic Carcinogens; 7 Genomics in Characterizing Endocrine Toxicity
8 Studying Organ-Specific Toxicity Using Gene-Expression Profiling9 Toxicogenomic Studies in Human Populations; 10 Toxicogenomics Applied to Ecological Risk Assessment; 11 Analysis of Transcriptomic Dose-Response Data for Toxicology and Risk Assessment; 12 Toxicogenomics as a Tool for Validating Animal to Human Extrapolations in Chemical Risk Assessment: Concepts, Applications, and Challenges; 13 Toxicogenomics and Animal Alternatives; 14 Toxicogenomics and the Regulatory Framework; 15 Standardization of Gene-Expression Information for the Safety Evaluation: Activities in Japan 16 Applying Transcriptional Profiling in Drug Safety Evaluation17 Reframing the Risk Assessment Paradigm: Toward a Systems Biology Approach; Index |
Record Nr. | UNINA-9910824275603321 |
Boverhof Darrell R
![]() |
||
Hoboken : , : Wiley, , 2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applied Health Economics - Second Edition [[electronic resource]] |
Autore | Jones Andrew M |
Edizione | [2nd ed.] |
Pubbl/distr/stampa | Hoboken, : Taylor and Francis, 2013 |
Descrizione fisica | 1 online resource (417 p.) |
Disciplina | 338.473621 |
Altri autori (Persone) |
RiceNigel
Bago d'UvaTeresa BaliaSilvia |
Collana | Routledge Advanced Texts in Economics and Finance |
Soggetto topico |
Economics, Medical
Health Care Costs Statistics as Topic Economics Delivery of Health Care Health Care Evaluation Mechanisms Costs and Cost Analysis Epidemiologic Methods Mathematics Investigative Techniques Health Care Quality, Access, and Evaluation Quality of Health Care Natural Science Disciplines Public Health Health Care Economics and Organizations Health Care Environment and Public Health Health & Biological Sciences Medical Economics |
Soggetto genere / forma | Electronic books. |
ISBN |
0-203-10241-X
1-136-23982-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title; Copyright; Contents; List of illustrations; Preface; Acknowledgements; Introduction; PART I Describing and summarising data; 1 Data and survey design; 1.1 The Health and Lifestyle Survey; 1.2 The British Household Panel Survey; 1.3 The European Community Household Panel; 1.4 The US Medical Expenditure Panel Survey; 1.5 Survey of Health, Ageing and Retirement in Europe; 1.6 Overview; 2 Describing the dynamics of health; 2.1 Introduction; 2.2 Graphical analysis; 2.3 Tabulating the data; 2.4 Overview; 3 Describing health care costs; 3.1 Introduction; 3.2 Data description
3.3 Modelling health care cost data3.4 Linear regression models; 3.5 Overview; PART II Categorical data; 4 Reporting heterogeneity in health; 4.1 Introduction; 4.2 Data; 4.3 Standard analysis; 4.4 Using vignettes; 4.5 Overview; Appendix; 5 Health and lifestyles; 5.1 Introduction; 5.2 HALS data and sample; 5.3 Descriptive analysis; 5.4 Estimation strategy and results; 5.5 Overview; PART III Duration data; 6 Smoking and mortality; 6.1 Introduction; 6.2 Basic concepts of duration analysis; 6.3 The HALS data; 6.4 Duration data in HALS; 6.5 Descriptive statistics; 6.6 Duration models; 6.7 Overview 7 Health and retirement7.1 Introduction; 7.2 Preparing and summarising the data; 7.3 Dealing with self-reported health; 7.4 Empirical approach to duration modelling; 7.5 Stock sampling and discrete-time hazard analysis; 7.6 Overview; PART IV Panel data; 8 Health and wages; 8.1 Introduction; 8.2 BHPS sample and variables; 8.3 Empirical model and estimation; 8.4 Overview; Appendix; 9 Modelling the dynamics of health; 9.1 Introduction; 9.2 Static models; 9.3 Dynamic models; 9.4 Overview; 10 Non-response and attrition bias; 10.1 Introduction; 10.2 Testing for non-response bias; 10.3 Estimation 10.4 OverviewAppendix; PART V Health care data; 11 Models for count data; 11.1 Introduction; 11.2 The Poisson model; 11.3 The negative binomial model; 11.4 Zero-inflated models; 11.5 Hurdle models; 11.6 Finite mixture/latent class models; 11.7 Latent class models for panel data; 11.8 Overview; Appendix; 12 Modelling health care costs; 12.1 Introduction; 12.2 Exponential conditional mean models; 12.3 Generalised linear models; 12.4 Finite mixture models; 12.5 Comparing model performance; 12.6 Overview; Bibliography; Index |
Record Nr. | UNINA-9910462932703321 |
Jones Andrew M
![]() |
||
Hoboken, : Taylor and Francis, 2013 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applied Health Economics - Second Edition [[electronic resource]] |
Autore | Jones Andrew M |
Edizione | [Second edition.] |
Pubbl/distr/stampa | Hoboken, : Taylor and Francis, 2013 |
Descrizione fisica | 1 online resource (417 pages) |
Disciplina | 338.473621 |
Altri autori (Persone) |
RiceNigel
Bago d'UvaTeresa <1976-> BaliaSilvia |
Collana | Routledge Advanced Texts in Economics and Finance |
Soggetto topico |
Economics, Medical
Health Care Costs Statistics as Topic Economics Delivery of Health Care Health Care Evaluation Mechanisms Costs and Cost Analysis Epidemiologic Methods Mathematics Investigative Techniques Health Care Quality, Access, and Evaluation Quality of Health Care Natural Science Disciplines Public Health Health Care Economics and Organizations Health Care Environment and Public Health Health & Biological Sciences Medical Economics |
ISBN |
0-203-10241-X
1-136-23982-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title; Copyright; Contents; List of illustrations; Preface; Acknowledgements; Introduction; PART I Describing and summarising data; 1 Data and survey design; 1.1 The Health and Lifestyle Survey; 1.2 The British Household Panel Survey; 1.3 The European Community Household Panel; 1.4 The US Medical Expenditure Panel Survey; 1.5 Survey of Health, Ageing and Retirement in Europe; 1.6 Overview; 2 Describing the dynamics of health; 2.1 Introduction; 2.2 Graphical analysis; 2.3 Tabulating the data; 2.4 Overview; 3 Describing health care costs; 3.1 Introduction; 3.2 Data description
3.3 Modelling health care cost data3.4 Linear regression models; 3.5 Overview; PART II Categorical data; 4 Reporting heterogeneity in health; 4.1 Introduction; 4.2 Data; 4.3 Standard analysis; 4.4 Using vignettes; 4.5 Overview; Appendix; 5 Health and lifestyles; 5.1 Introduction; 5.2 HALS data and sample; 5.3 Descriptive analysis; 5.4 Estimation strategy and results; 5.5 Overview; PART III Duration data; 6 Smoking and mortality; 6.1 Introduction; 6.2 Basic concepts of duration analysis; 6.3 The HALS data; 6.4 Duration data in HALS; 6.5 Descriptive statistics; 6.6 Duration models; 6.7 Overview 7 Health and retirement7.1 Introduction; 7.2 Preparing and summarising the data; 7.3 Dealing with self-reported health; 7.4 Empirical approach to duration modelling; 7.5 Stock sampling and discrete-time hazard analysis; 7.6 Overview; PART IV Panel data; 8 Health and wages; 8.1 Introduction; 8.2 BHPS sample and variables; 8.3 Empirical model and estimation; 8.4 Overview; Appendix; 9 Modelling the dynamics of health; 9.1 Introduction; 9.2 Static models; 9.3 Dynamic models; 9.4 Overview; 10 Non-response and attrition bias; 10.1 Introduction; 10.2 Testing for non-response bias; 10.3 Estimation 10.4 OverviewAppendix; PART V Health care data; 11 Models for count data; 11.1 Introduction; 11.2 The Poisson model; 11.3 The negative binomial model; 11.4 Zero-inflated models; 11.5 Hurdle models; 11.6 Finite mixture/latent class models; 11.7 Latent class models for panel data; 11.8 Overview; Appendix; 12 Modelling health care costs; 12.1 Introduction; 12.2 Exponential conditional mean models; 12.3 Generalised linear models; 12.4 Finite mixture models; 12.5 Comparing model performance; 12.6 Overview; Bibliography; Index |
Record Nr. | UNINA-9910786719003321 |
Jones Andrew M
![]() |
||
Hoboken, : Taylor and Francis, 2013 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applied Health Economics - Second Edition [[electronic resource]] |
Autore | Jones Andrew M |
Edizione | [Second edition.] |
Pubbl/distr/stampa | Hoboken, : Taylor and Francis, 2013 |
Descrizione fisica | 1 online resource (417 pages) |
Disciplina | 338.473621 |
Altri autori (Persone) |
RiceNigel
Bago d'UvaTeresa <1976-> BaliaSilvia |
Collana | Routledge Advanced Texts in Economics and Finance |
Soggetto topico |
Economics, Medical
Health Care Costs Statistics as Topic Economics Delivery of Health Care Health Care Evaluation Mechanisms Costs and Cost Analysis Epidemiologic Methods Mathematics Investigative Techniques Health Care Quality, Access, and Evaluation Quality of Health Care Natural Science Disciplines Public Health Health Care Economics and Organizations Health Care Environment and Public Health Health & Biological Sciences Medical Economics |
ISBN |
0-203-10241-X
1-136-23982-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title; Copyright; Contents; List of illustrations; Preface; Acknowledgements; Introduction; PART I Describing and summarising data; 1 Data and survey design; 1.1 The Health and Lifestyle Survey; 1.2 The British Household Panel Survey; 1.3 The European Community Household Panel; 1.4 The US Medical Expenditure Panel Survey; 1.5 Survey of Health, Ageing and Retirement in Europe; 1.6 Overview; 2 Describing the dynamics of health; 2.1 Introduction; 2.2 Graphical analysis; 2.3 Tabulating the data; 2.4 Overview; 3 Describing health care costs; 3.1 Introduction; 3.2 Data description
3.3 Modelling health care cost data3.4 Linear regression models; 3.5 Overview; PART II Categorical data; 4 Reporting heterogeneity in health; 4.1 Introduction; 4.2 Data; 4.3 Standard analysis; 4.4 Using vignettes; 4.5 Overview; Appendix; 5 Health and lifestyles; 5.1 Introduction; 5.2 HALS data and sample; 5.3 Descriptive analysis; 5.4 Estimation strategy and results; 5.5 Overview; PART III Duration data; 6 Smoking and mortality; 6.1 Introduction; 6.2 Basic concepts of duration analysis; 6.3 The HALS data; 6.4 Duration data in HALS; 6.5 Descriptive statistics; 6.6 Duration models; 6.7 Overview 7 Health and retirement7.1 Introduction; 7.2 Preparing and summarising the data; 7.3 Dealing with self-reported health; 7.4 Empirical approach to duration modelling; 7.5 Stock sampling and discrete-time hazard analysis; 7.6 Overview; PART IV Panel data; 8 Health and wages; 8.1 Introduction; 8.2 BHPS sample and variables; 8.3 Empirical model and estimation; 8.4 Overview; Appendix; 9 Modelling the dynamics of health; 9.1 Introduction; 9.2 Static models; 9.3 Dynamic models; 9.4 Overview; 10 Non-response and attrition bias; 10.1 Introduction; 10.2 Testing for non-response bias; 10.3 Estimation 10.4 OverviewAppendix; PART V Health care data; 11 Models for count data; 11.1 Introduction; 11.2 The Poisson model; 11.3 The negative binomial model; 11.4 Zero-inflated models; 11.5 Hurdle models; 11.6 Finite mixture/latent class models; 11.7 Latent class models for panel data; 11.8 Overview; Appendix; 12 Modelling health care costs; 12.1 Introduction; 12.2 Exponential conditional mean models; 12.3 Generalised linear models; 12.4 Finite mixture models; 12.5 Comparing model performance; 12.6 Overview; Bibliography; Index |
Record Nr. | UNINA-9910824051303321 |
Jones Andrew M
![]() |
||
Hoboken, : Taylor and Francis, 2013 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Assessment and Reclamation of Contaminated Land [[electronic resource]] |
Autore | Harrison Roy M. <1948-> |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Cambridge, : Royal Society of Chemistry, 2001 |
Descrizione fisica | 1 online resource (180 p.) |
Disciplina | 628.55 |
Altri autori (Persone) |
HesterR. E
PollardS.imon |
Collana | Issues in Environmental Science and Technology |
Soggetto topico |
Reclamation of land -- Great Britain
Soil pollution -- Great Britain Soil pollution -- Law and legislation -- Great Britain Soil remediation -- Great Britain Soil pollution - Law and legislation - Great Britain Soil pollution - Great Britain Soil remediation - Great Britain Reclamation of land - Great Britain Risk Management Risk Epidemiologic Measurements Environmental Pollutants Public Health Probability Toxic Actions Organization and Administration Statistics as Topic Chemical Actions and Uses Environment and Public Health Health Services Administration Health Care Epidemiologic Methods Health Care Evaluation Mechanisms Investigative Techniques Quality of Health Care Health Care Quality, Access, and Evaluation Soil Pollutants Risk Assessment Civil & Environmental Engineering Engineering & Applied Sciences Environmental Engineering |
ISBN |
1-84755-017-7
1-59124-419-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
CONTENTS; The Extent of Contaminated Land Problems and the Scientific Response; 1 The Origins of Contaminated Land Problems; 2 The Extent of the Challenge; 3 Developments in the Science Base; 4 Conclusions; 5 Acknowledgements; The New UK Contaminated Land Regime; 1 Introduction; 2 The Context forPart IIA; 3 The Part IIA System; 4 Dealing with 'Risk'; 5 Making People Pay; 6 Part IIA as a 'Regulatory System'; 7 The State of Play; 8 What Next?; Identifying and Dealing with Contaminated Land; 1 Introduction; 2 Site Assessment; 3 Risk Management; 4 Measurement of Site Contamination; 5 Conclusions
Contaminated Land and the Link with Health1 Introduction; 2 Exposure; 3 Health Studies; 4 Case Studies; 5 Conclusion; Human Health Risk Assessment: Guideline Values and Magic Numbers; 1 Land Contamination Policy; 2 Risk Assessment; 3 What Is a Guideline Value?; 4 The Use of Guideline Values; 5 The CLEA Model; 6 The SNIFFER Framework; 7 Conclusions; 8 Acknowledgements; Ecological Risk Assessment under the New Contaminated Land Regime; 1 Background and Legal Context; 2 Harm to Ecological Receptors; 3 General Approach to the Assessment of Land Under the NewRegime 4 Assessing Whether Significant Harm to Ecological Receptors Is Occurring5 Assessing the Possibility of Significant Harm Occurring; 6 The Environment Agency's Suggested Approach; 7 Guideline Values; 8 Comments and Discussion; Remediation Methods for Contaminated Sites; 1 Introduction; 2 Summary of Remediation Approaches; 3 Selected Innovative Approaches; 4 Summary and Conclusions; Legal Liabilities and Insurance Aspects of Contaminated Land; 1 Introduction; 2 Contaminated Land; 3 Statutory Provisions in the UK; 4 Sale of Land/Businesses; 5 Principles of Insurance 6 History of Environmental Insurance7 Land Owners and Environmental Liabilities; 8 Pollution Liabilities for Contaminated Land Sites; 9 Current Manufacturing Activities; 10 Environmental Insurance; 11 Environmental Consultants; 12 Collateral Warranties; 13 Contractors; 14 An Example; 15 Conclusion; Subject Index |
Record Nr. | UNINA-9910142515703321 |
Harrison Roy M. <1948->
![]() |
||
Cambridge, : Royal Society of Chemistry, 2001 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program [[electronic resource]] |
Autore | Staff Institute of Medicine |
Pubbl/distr/stampa | Washington, : National Academies Press, 2002 |
Descrizione fisica | 1 online resource (179 p.) |
Disciplina | 615 |
Soggetto topico |
Anthrax -- Vaccination
Public health Anthrax - Vaccination - Research - United States Bacterial Vaccines Evaluation Studies as Topic Health Care Evaluation Mechanisms Quality of Health Care Bacillaceae Infections Investigative Techniques Vaccines Health Services Administration Gram-Positive Bacterial Infections Bacterial Infections Health Care Quality, Access, and Evaluation Health Care Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Products Complex Mixtures Bacterial Infections and Mycoses Chemicals and Drugs Diseases Program Evaluation Drug Evaluation Anthrax Anthrax Vaccines Public Health Health & Biological Sciences Communicable Diseases |
Soggetto genere / forma | Electronic books. |
ISBN | 0-309-50374-4 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Front Matter""; ""Preface""; ""Reviewers""; ""Contents""; ""Figures, Tables, and Boxes""; ""Abbreviations and Acronyms""; ""Executive Summary""; ""1 Introduction""; ""2 Background""; ""3 The CDC Anthrax Vaccine Research Plan""; ""4 Proposed Studies on the Efficacy of the Anthrax Vaccine""; ""5 Proposed Studies on the Safety of the Anthrax Vaccine""; ""6 Proposed Studies on the Acceptability of the Anthrax Vaccine""; ""7 Summary Assessment of the CDC Anthrax Vaccine Research Plan""; ""Appendix A Biographical Sketches""; ""Appendix B Information-Gathering Meeting Agendas""
""Appendix C Anthrax Vaccine Safety & Efficacy Research Plan""""Appendix D Food and Drug Administration Final Rule: New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible""; ""Appendix E Department of Defense Memorandum: Reintroduction of the Anthrax Vaccine Immunization Program""; ""Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1"" ""Appendix G Institute of Medicine: The Anthrax Vaccine: Is It Safe? Does It Work? Findings and Recommendations1"" |
Record Nr. | UNINA-9910455868803321 |
Staff Institute of Medicine
![]() |
||
Washington, : National Academies Press, 2002 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|